Core Insights - Roche has introduced its proprietary sequencing by expansion (SBX) technology, which establishes a new category in next-generation sequencing, offering ultra-rapid, high-throughput, flexible, and scalable sequencing solutions [1][3][5] Technology Overview - SBX technology utilizes a sophisticated biochemical process to encode the sequence of target nucleic acid molecules into a surrogate polymer called an Xpandomer, which is fifty times longer than the original molecule, enhancing signal clarity and accuracy [3][7] - The technology integrates a high-throughput CMOS sensor module that allows for real-time base calls and analysis, enabling simultaneous processing of numerous samples, thus providing scalability and flexibility for various project sizes [7][8] Applications and Impact - SBX technology is suitable for a wide range of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing, making it valuable for both research laboratories and clinical settings [8][9] - The technology has the potential to significantly speed up genomic research and clinical applications by reducing the time from sample to genome from days to hours, which could enhance understanding of complex diseases such as cancer and neurodegenerative conditions [9] Company Background - Roche, founded in 1896, is a leading biotechnology company and global leader in in-vitro diagnostics, committed to scientific excellence and personalized healthcare [12][13] - The SBX technology was developed by Mark Kokoris and Robert McRuer, who co-founded Stratos Genomics, acquired by Roche in 2020, indicating Roche's ongoing investment in innovative genomic technologies [10]
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology